On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, ...
Latest released the research study on Global Iron Sucrose Injection Market , offers a detailed overview of the factors influencing the global business scope. Iron Sucrose Injection Market research ...
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with ...
Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic product targeting Venofer marketed by Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) ...
Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH, Aug. 11, 2025 /PRNewswire/ -- Viatris ...
Amphastar Pharmaceuticals, Inc. AMPH, a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results